MedPath

DICLOFENAC SODIUM

These highlights do not include all the information needed to use DICLOFENACSODIUM TOPICAL SOLUTION safely and effectively. See full prescribing information for DICLOFENAC SODIUM TOPICAL SOLUTION. DICLOFENAC SODIUM topical solution, USP 2% w/w for topical use Initial U.S. Approval: 1988

Approved
Approval ID

e7304b3e-530a-4519-aed0-bed4512d8925

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Apr 18, 2025

Manufacturers
FDA

Encube Ethicals Private Limited

DUNS: 915834105

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

DICLOFENAC

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code21922-033
Application NumberANDA217646
Product Classification
M
Marketing Category
C73584
G
Generic Name
DICLOFENAC
Product Specifications
Route of AdministrationTOPICAL
Effective DateApril 18, 2025
FDA Product Classification

INGREDIENTS (6)

WATERInactive
Code: 059QF0KO0R
Classification: IACT
DICLOFENAC SODIUMActive
Quantity: 20 mg in 1 g
Code: QTG126297Q
Classification: ACTIB
DIMETHYL SULFOXIDEInactive
Code: YOW8V9698H
Classification: IACT
ALCOHOLInactive
Code: 3K9958V90M
Classification: IACT
HYDROXYPROPYL CELLULOSE (430000 WAMW)Inactive
Code: VQ8ZWO78F6
Classification: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3
Classification: IACT

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 4/16/2025

BOXED WARNING SECTION

LOINC: 34066-1Updated: 4/16/2025

INDICATIONS & USAGE SECTION

LOINC: 34067-9Updated: 4/16/2025

CONTRAINDICATIONS SECTION

LOINC: 34070-3Updated: 4/16/2025

WARNINGS AND PRECAUTIONS SECTION

LOINC: 43685-7Updated: 4/16/2025

ADVERSE REACTIONS SECTION

LOINC: 34084-4Updated: 4/16/2025

DRUG INTERACTIONS SECTION

LOINC: 34073-7Updated: 4/16/2025

RECENT MAJOR CHANGES SECTION

LOINC: 43683-2Updated: 4/16/2025

DOSAGE & ADMINISTRATION SECTION

LOINC: 34068-7Updated: 4/16/2025

DOSAGE FORMS & STRENGTHS SECTION

LOINC: 43678-2Updated: 4/16/2025

USE IN SPECIFIC POPULATIONS SECTION

LOINC: 43684-0Updated: 4/16/2025

OVERDOSAGE SECTION

LOINC: 34088-5Updated: 4/16/2025

DESCRIPTION SECTION

LOINC: 34089-3Updated: 4/16/2025

CLINICAL PHARMACOLOGY SECTION

LOINC: 34090-1Updated: 4/16/2025

NONCLINICAL TOXICOLOGY SECTION

LOINC: 43680-8Updated: 4/16/2025

CLINICAL STUDIES SECTION

LOINC: 34092-7Updated: 4/16/2025

HOW SUPPLIED SECTION

LOINC: 34069-5Updated: 4/16/2025

INFORMATION FOR PATIENTS SECTION

LOINC: 34076-0Updated: 4/16/2025

SPL UNCLASSIFIED SECTION

LOINC: 42229-5Updated: 4/16/2025

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.